License Agreement with Duke - Additional Information (Detail)
|
|
|
|
3 Months Ended |
|
|
|
|
Feb. 17, 2023
USD ($)
Patients
|
Feb. 04, 2022
USD ($)
|
Feb. 23, 2021
USD ($)
|
Feb. 28, 2023
USD ($)
ft²
shares
|
Feb. 28, 2022
USD ($)
|
Feb. 23, 2023
USD ($)
|
Feb. 28, 2021
USD ($)
|
Dec. 01, 2020
USD ($)
|
| Patent Option And Technology License Agreement [Line Items] |
|
|
|
|
|
|
|
|
| Revenue |
|
|
|
$ 7,824,415
|
$ 7,258,531
|
|
|
|
| Duke University [Member] |
|
|
|
|
|
|
|
|
| Patent Option And Technology License Agreement [Line Items] |
|
|
|
|
|
|
|
|
| License fee payable |
|
|
|
|
|
$ 2,000,000
|
|
$ 12,000,000
|
| Milestone payments first phase III clinical trial |
|
$ 2,000,000
|
$ 2,000,000
|
|
|
|
|
|
| Capitalized costs to obtain agreement |
|
|
|
|
|
|
$ 15,372,382
|
|
| Present value of license fee |
|
|
|
12,000,000
|
|
|
|
|
| Number of common stock value transferred |
|
|
|
$ 3,585,172
|
|
|
|
|
| Number of common stock shares transferred | shares |
|
|
|
409,734
|
|
|
|
|
| Capitalized costs amortization period |
|
|
|
16 years
|
|
|
|
|
| Amortization expense |
|
|
|
$ 240,193
|
$ 240,193
|
|
|
|
| Duke University [Member] | 5.0% upon Execution of the Agreement [Member] | Fully Diluted Equity Ownership |
|
|
|
|
|
|
|
|
| Patent Option And Technology License Agreement [Line Items] |
|
|
|
|
|
|
|
|
| Common Stock Equal Full Diluted Equity Ownership Outstanding Percentage |
|
|
5.00%
|
|
|
|
|
|
| Duke University [Member] | 2.5% Market Cap [Member] | Fully Diluted Equity Ownership |
|
|
|
|
|
|
|
|
| Patent Option And Technology License Agreement [Line Items] |
|
|
|
|
|
|
|
|
| Common Stock Equal Full Diluted Equity Ownership Outstanding Percentage |
|
|
2.50%
|
|
|
|
|
|
| Duke University [Member] | Minimum [Member] |
|
|
|
|
|
|
|
|
| Patent Option And Technology License Agreement [Line Items] |
|
|
|
|
|
|
|
|
| Royalties Percentage Portion of Net Sales |
|
|
7.00%
|
|
|
|
|
|
| Duke University [Member] | Minimum [Member] | 2.5% Market Cap Triggers with 18 Months [Member] | Fully Diluted Equity Ownership |
|
|
|
|
|
|
|
|
| Patent Option And Technology License Agreement [Line Items] |
|
|
|
|
|
|
|
|
| Average Closing Market Capital |
|
|
$ 300,000,000
|
|
|
|
|
|
| Duke University [Member] | Minimum [Member] | 2.5% Market Cap Triggers with 24 Months [Member] | Fully Diluted Equity Ownership |
|
|
|
|
|
|
|
|
| Patent Option And Technology License Agreement [Line Items] |
|
|
|
|
|
|
|
|
| Average Closing Market Capital |
|
|
$ 500,000,000
|
|
|
|
|
|
| Duke University [Member] | Maximum [Member] |
|
|
|
|
|
|
|
|
| Patent Option And Technology License Agreement [Line Items] |
|
|
|
|
|
|
|
|
| Royalties Percentage Portion of Net Sales |
|
|
12.50%
|
|
|
|
|
|
| Duke University [Member] | Within Fourteen (14) days of February 23, 2021 |
|
|
|
|
|
|
|
|
| Patent Option And Technology License Agreement [Line Items] |
|
|
|
|
|
|
|
|
| License fee payable |
|
|
$ 10,000,000
|
|
|
|
|
|
| Duke University [Member] | Second Anniversary [Member] |
|
|
|
|
|
|
|
|
| Patent Option And Technology License Agreement [Line Items] |
|
|
|
|
|
|
|
|
| Minimum Annual Royalties Due Year Two |
|
|
500,000
|
|
|
|
|
|
| Minimum Annual Royalties Due Year Three |
|
|
1,000,000
|
|
|
|
|
|
| Minimum Annual Royalties Due Year Four |
|
|
2,500,000
|
|
|
|
|
|
| Minimum Annual Royalties Due Year Five |
|
|
5,000,000
|
|
|
|
|
|
| Minimum Annual Royalties Due After Year Five |
|
|
$ 5,000,000
|
|
|
|
|
|
| Duke University [Member] | Third Anniversary [Member] |
|
|
|
|
|
|
|
|
| Patent Option And Technology License Agreement [Line Items] |
|
|
|
|
|
|
|
|
| Minimum Annual Royalties Due Year Three |
|
500,000
|
|
|
|
|
|
|
| Minimum Annual Royalties Due Year Four |
|
1,000,000
|
|
|
|
|
|
|
| Minimum Annual Royalties Due Year Five |
|
2,500,000
|
|
|
|
|
|
|
| Minimum Annual Royalties Due Year Six |
|
5,000,000
|
|
|
|
|
|
|
| Minimum Annual Royalties Due After Year Six |
|
$ 5,000,000
|
|
|
|
|
|
|
| Duke University [Member] | Licensed Product and Licensed Process [Member] |
|
|
|
|
|
|
|
|
| Patent Option And Technology License Agreement [Line Items] |
|
|
|
|
|
|
|
|
| Area of medical condominium building | ft² |
|
|
|
56,000
|
|
|
|
|
| Royalties Term |
|
|
|
15 years
|
|
|
|
|
| Duke University [Member] | Licensed Product and Licensed Process [Member] | 2.5% Upon Cumulative Net Sales [Member] | Fully Diluted Equity Ownership |
|
|
|
|
|
|
|
|
| Patent Option And Technology License Agreement [Line Items] |
|
|
|
|
|
|
|
|
| Common Stock Equal Full Diluted Equity Ownership Outstanding Percentage |
|
|
2.50%
|
|
|
|
|
|
| Revenue |
|
|
$ 10,000,000
|
|
|
|
|
|
| Duke University [Member] | Licensed Product and Licensed Process [Member] | 2.5% Upon Cumulative Net Sales [Member] | Fully Diluted Equity Ownership |
|
|
|
|
|
|
|
|
| Patent Option And Technology License Agreement [Line Items] |
|
|
|
|
|
|
|
|
| Common Stock Equal Full Diluted Equity Ownership Outstanding Percentage |
|
|
2.50%
|
|
|
|
|
|
| Revenue |
|
|
$ 75,000,000
|
|
|
|
|
|
| Second Amendment to the License Agreement [Member] |
|
|
|
|
|
|
|
|
| Patent Option And Technology License Agreement [Line Items] |
|
|
|
|
|
|
|
|
| Payment towards funding and completion of study |
$ 2,000,000
|
|
|
|
|
|
|
|
| Research Agreement [Member] |
|
|
|
|
|
|
|
|
| Patent Option And Technology License Agreement [Line Items] |
|
|
|
|
|
|
|
|
| Additional Consideration Payable |
2,000,000
|
|
|
|
|
|
|
|
| Monthly instalment payable |
187,407
|
|
|
|
|
|
|
|
| Consideration payable for research |
$ 187,400
|
|
|
|
|
|
|
|
| Number of patients in trial's targeted accrual | Patients |
137
|
|
|
|
|
|
|
|